BioNTech and Bristol will evenly split the costs of developing and commercializing BNT327, and will "work jointly to broaden and accelerate the development of this clinical candidate." The drug is ...
An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...
InvestorsHub on MSN
Leerink cuts BioNTech to "market perform" after shares surge 24%
BioNTech SE (F:22UAy) (NASDAQ:BNTX) has been downgraded to “market perform” from “outperform” by Leerink Partners after a ...
Phase 1/2a trial of BNT324/DB-1311 in solid tumors showed a 32.4% unconfirmed objective response rate and 82.4% disease control rate. BNT324/DB-1311 showed a manageable safety profile across all ...
Hosted on MSN
Why BioNTech Stock Jumped by Nearly 4% on Wednesday
The biotech continues to embrace artificial intelligence (AI) technology, which is heartening for investors. It owns and manages an AI developer, InstaDeep. 10 stocks we like better than BioNTech Se › ...
BioNTech SE (NASDAQ:BNTX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are covering the company, MarketBeat.com reports. Three research ...
Coronavirus vaccine developers could soon be forced to absorb a hit to their reputation. Apparently, government officials are to recommend to an influential healthcare panel that such products are ...
BioNTech (NASDAQ:BNTX) announced Tuesday that its mRNA-based cancer therapy BNT111, in combination with Regeneron’s (NASDAQ:REGN) anti-PD-1 therapy, Libtayo (cemiplimab), succeeded in a Phase 2 trial ...
A new federal government appointment had investors worried about vaccine makers. This was compounded by an analyst's price target cut for the German biotech. The Food and Drug Administration (FDA), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results